{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:15:57Z","timestamp":1779228957906,"version":"3.51.4"},"reference-count":17,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy of data in this population. Two hemodialysis patient cases of contrasting responses in parathyroid hormone (PTH) after denosumab administration were observed. Patient 1, a 62-years-old male received denosumab 60 mg at Day 0. His calcium decreased from 8.8 mg\/dL to 6.8 mg\/dL on Day 30. The PTH level increased from 265 pg\/mL to 372 pg\/mL after 30 days. Calcium and PTH levels approached normal range after increasing doses of vitamin D\/calcium supplements, and calcitriol. Patient 2, a 72-years-old male on hemodialysis also received denosumab 60 mg on Day 0. His baseline calcium and PTH were 9.2 mg\/dL and 420 pg\/mL, respectively. On Day 30, his calcium level decreased (6.8 mg\/dL) but, PTH level drastically increased (&gt;5000 pg\/mL). Denosumab commonly causes hypocalcemia and hyperparathyroidism since it inhibits osteoclast activation, reduces calcium release from bone and increases PTH levels as a compensatory mechanism. With a wait-and-watch approach, Patient 2\u2019s levels approached the normal range (calcium 9.6 mg\/dL and PTH 274 pg\/mL at Day 90).<\/jats:p>","DOI":"10.3390\/pharmacy8020059","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T05:52:30Z","timestamp":1585720350000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-7210","authenticated-orcid":false,"given":"Soo Min","family":"Jang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA 92350, USA"},{"name":"Loma Linda University Kidney Center, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smitha","family":"Anam","sequence":"additional","affiliation":[{"name":"Pacific Nephrology, Concord, CA 94520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Pringle","sequence":"additional","affiliation":[{"name":"Loma Linda University Kidney Center, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lahren","sequence":"additional","affiliation":[{"name":"Loma Linda University Kidney Center, Loma Linda, CA 92354, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Infante","sequence":"additional","affiliation":[{"name":"Loma Linda University Kidney Center, Loma Linda, CA 92354, USA"},{"name":"Department of Internal Medicine Nephrology Division, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Amgen Inc. (2017). Prolia (Denosumab) [Package Insert], Amgen Inc."},{"key":"ref_5","first-page":"3027419","article-title":"Severe Hypocalcemia and Dramatic Increase in Parathyroid Hormone after Denosumab in a Dialysis Patient: A Case Report and Review of the Literature","volume":"2019","author":"Bhanot","year":"2019","journal-title":"Case Rep. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: A meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","article-title":"Safety and efficacy of denosumab in osteoporotic hemodialysed patients","volume":"30","author":"Festuccia","year":"2017","journal-title":"J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/imj.13097","article-title":"Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease","volume":"46","author":"Killen","year":"2016","journal-title":"Intern. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jc.2015-1259","article-title":"Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass","volume":"100","author":"Chen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: Safety and efficacy appraisal of denosumab","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","article-title":"Severe hypocalcemia following denosumab injection in a hemodialysis patient","volume":"60","author":"McCormick","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.ajkd.2015.03.012","article-title":"Denosumab for low bone mass in hemodialysis patients: A noncontrolled trial","volume":"66","author":"Hiramatsu","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6218129","DOI":"10.1155\/2017\/6218129","article-title":"Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study","volume":"2017","author":"Takami","year":"2017","journal-title":"Int. J. Nephrol."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/2\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:14:02Z","timestamp":1760174042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/8\/2\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["pharmacy8020059"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy8020059","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}